Related Experiment Video
Updated: Jul 31, 2025
A Protocol for Rapid Post-mortem Cell Culture of Diffuse Intrinsic Pontine Glioma DIPG
Published on: March 7, 2017
Pediatric diffuse midline glioma: Understanding the mechanisms and assessing the next generation of personalized
Nicolina Jovanovich1, Ahmed Habib2,1, Jeffery Head2
1Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
Abstract:
Diffuse midline glioma (DMG) is a pediatric cancer that originates in the midline structures of the brain. Prognosis of DMG patients remains poor due to the infiltrative nature of these tumors and the protection they receive from systemically delivered therapeutics via an intact blood-brain barrier (BBB), making treatment difficult. While the cell of origin remains disputed, it is believed to reside in the ventral pons. Recent research has pointed toward epigenetic dysregulation inducing an OPC-like transcriptomic signature in DMG cells. This epigenetic dysregulation is typically caused by a mutation (K27M) in one of two histone genes-H3F3A or HIST1H3B -and can lead to a differentiation block that increases these cells oncogenic potential. Standard treatment with radiation is not sufficient at overcoming the aggressivity of this cancer and only confers a survival benefit of a few months, and thus, discovery of new therapeutics is of utmost importance. In this review, we discuss the cell of origin of DMGs, as well as the underlying molecular mechanisms that contribute to their aggressivity and resistance to treatment. Additionally, we outline the current standard of care for DMG patients and the potential future therapeutics for this cancer that are currently being tested in preclinical and clinical trials.
Insights
Diffuse midline glioma (DMG) is a pediatric brain cancer with poor prognosis. New therapeutics are crucial due to treatment resistance and limited survival benefits from standard care.
Area of Science:
- Pediatric oncology
- Neuro-oncology
- Cancer epigenetics
Background:
- Diffuse midline glioma (DMG) is an aggressive pediatric brain cancer.
- Poor prognosis is linked to tumor infiltrative nature and blood-brain barrier (BBB) protection.
- Epigenetic dysregulation, often via K27M histone mutations, drives DMG oncogenesis.
Purpose of the Study:
- To review the cell of origin for DMGs.
- To discuss molecular mechanisms of DMG aggressivity and treatment resistance.
- To outline current standards of care and emerging therapeutics for DMG.
Main Methods:
- Literature review of DMG research.
- Analysis of molecular mechanisms including epigenetics and transcriptomics.
- Summary of preclinical and clinical trial data for novel therapeutics.
Main Results:
- DMG origin is likely in the ventral pons, with epigenetic alterations causing an OPC-like signature.
- Histone gene mutations (K27M) in H3F3A or HIST1H3B lead to differentiation block and increased oncogenic potential.
- Radiation therapy offers limited survival benefit, highlighting the need for new treatments.
Conclusions:
- Understanding DMG's cell of origin and molecular drivers is key.
- Novel therapeutic strategies are under investigation to overcome treatment resistance.
- Future treatments aim to improve survival outcomes for pediatric DMG patients.
